Stoekenbroek, Robert M.

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P. (2019) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 172

Hyperbaric oxygen therapy in the treatment of ischemic lower- extremity ulcers in patients with diabetes: results of the DAMO2CLES multicenter randomized clinical trial.

Santema, K. T. B., Stoekenbroek, R. M., Koelemay, M. J. W., Reekers, J. A., van Dortmont, L. M. C., Oomen, A., Smeets, L., Wever, J. J., Legemate, D. A., Ubbink, D. T., et al. (2018) · Diabetes Care

Diabetic Foot Ulcer Assessment and ManagementPeripheral Artery Disease Management

Cited by 170

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P., & Kastelein, J. J. P. (2018) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 154

Inhibiting PCSK9 — biology beyond LDL control

Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 141

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Hovingh, G. K., Lepor, N. E., Kallend, D., Stoekenbroek, R. M., Wijngaard, P. L. J., & Raal, F. J. (2020) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 113

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

Landmesser, U., Haghikia, A., Leiter, L. A., Wright, R. S., Kallend, D., Wijngaard, P., Stoekenbroek, R., Kastelein, J. J., & Ray, K. K. (2021) · Cardiovascular Research

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 83

Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Kallend, D., Stoekenbroek, R., He, Y., Smith, P. F., & Wijngaard, P. (2022) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Stoekenbroek, R. M., Boekholdt, S. M., Fayyad, R., Laskey, R., Tikkanen, M. J., Pedersen, T. R., & Hovingh, G. K. (2015) · Heart

Lipoproteins and Cardiovascular HealthPeripheral Artery Disease Management

Cited by 44